• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 11, 2023 at 12:32: PM
via Mirati Therapeutics has reported that Krazati demonstrated durable efficacy in a two-year follow-up from a Phase I/Ib and Phase II trial for patients with non-small cell lung cancer (NSCLC).

article source
 




Top Bottom
Back
Quote